Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

Probing the Functional and Behavioral Impact of Precision Circuit Modulation in Neuropsychiatric Diseases

Repetitive transcranial magnetic stimulation (rTMS) is a way of non-invasively stimulating specific brain networks and is an established treatment for Major Depressive Disorder (MDD). This proposal will reveal network mechanisms of the therapeutic effects of rTMS by investigating how stimulating each network specifically changes network connectivity and behavior. This will be done in a highly individualized manner in depressed and healthy patients, leading to more effective and more individualized treatments for depression.

Study Overview

• Status: Recruiting
• Conditions: Major Depressive Disorder
• Intervention / Treatment: Device: Intermittent Theta Burst Stimulation (iTBS)

Detailed Description

Network models are increasingly invoked to characterize the neurobiological underpinnings of mental illnesses. Dysfunction within specific circuits promotes the formation of specific symptoms. This suggests an opportunity to treat specific symptoms by modulating specific circuits. Repetitive transcranial magnetic stimulation (rTMS) is capable of circuit-specific neuromodulation. It is also an established treatment for Major Depressive Disorder (MDD). Clinical experience suggests that rTMS treats different symptom constructs by stimulating different circuits. However, there remains a critical lack of mechanistic evidence to support putative network mechanisms of rTMS, limiting its ability to treat patients with more personalized and optimized approaches. This mechanistic proposal will first use resting-state functional connectivity (FC) MRI and customized analytic pipelines to characterize functional network topography in healthy and depressed individuals at high resolution.This data will be used to derive rTMS targets functionally situated in discrete prefrontal networks (e.g., control, default, salience, limbic/reward). Next, patients will take part in a within-subject design in which they undergo rTMS to each target on separate days. Each target will be stimulated four times on a given day, and after each stimulation changes will be measured with: (1) REST-BOLD MRI (to assess FC changes), (2) TASK-BOLD MRI (to assess changes in BOLD activation on paradigms validated to test RDoC constructs), (3) state-based questionnaires or (4) neuropsychological tests. This work will facilitate individualized neuromodulation approaches based on network topography. This will pollinate large-scale clinical trials assessing the effects of differential circuit modulation. It will also illuminate circuit-construct relationships across neuropsychiatric disorders.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02129
      • Recruiting
      • Massachusetts General Hospital
      • Contact: Mark Eldaief, MD; Phone Number: 617-726-1728; Email: meldaief@partners.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria for healthy participants:

• 18-65 years of age
• Capacity to provide informed consent form to participate in the study

Inclusion Criteria for participants with Major Depressive Disorder (MDD):

• 18-65 years of age
• Capacity to provide informed consent form to participate in the study
• Currently in a major depressive episode. Comorbid anxiety disorders and personality disorders will be allowed provided that MDD is the primary diagnosis.

Exclusion Criteria for all participants:

• Meeting criteria, in the past or currently, for bipolar affective disorder, hypomania or mania.
• Meeting criteria, in the past or currently, for a primary psychotic disorder (e.g., schizophrenia).
• Neurological conditions with known structural brain lesions, e.g., intracranial masses, multiple sclerosis.
• Any personal history of seizures or a family history of epilepsy in a first-degree relative.
• Metal in the body that is ferromagnetic or metallic injury to the eyes.
• Implanted pacemakers, medication pumps, vagal stimulators, deep brain stimulators, or ventriculoperitoneal shunts, etc.
• Substance abuse or dependence that is current and active within the last six months, as indicated by self-report (e.g., heroin, cocaine, methamphetamines).
• Inability to meet the safety criteria for MRI scanning for any other reason.
• Severe or unstable medical illness.
• Currently pregnant, as assessed with urine pregnancy test in women of childbearing age.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DLPFC Salience network target; iTBS delivered four times daily to an individually defined salience network representation in left dorsolateral prefrontal cortex (DLPFC).	Device: Intermittent Theta Burst Stimulation (iTBS); iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.; Other Names: Repetitive Transcranial Magnetic Stimulation
Experimental: DLPFC Control network target; iTBS delivered four times daily to an individually defined control network representation in left dorsolateral prefrontal cortex (DLPFC).	Device: Intermittent Theta Burst Stimulation (iTBS); iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.; Other Names: Repetitive Transcranial Magnetic Stimulation
Experimental: DLPFC Default network A target; iTBS delivered four times daily to an individually defined default network A representation in left dorsolateral prefrontal cortex (DLPFC).	Device: Intermittent Theta Burst Stimulation (iTBS); iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.; Other Names: Repetitive Transcranial Magnetic Stimulation
Experimental: dmPFC Default network B target; iTBS delivered four times daily to an individually defined default network B representation in left dorsomedial prefrontal cortex (DMPFC).	Device: Intermittent Theta Burst Stimulation (iTBS); iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.; Other Names: Repetitive Transcranial Magnetic Stimulation
Experimental: vmPFC limbic-reward network target; iTBS delivered four times daily to an individually defined reward network representation in left ventromedial prefrontal cortex (vMPFC).	Device: Intermittent Theta Burst Stimulation (iTBS); iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.; Other Names: Repetitive Transcranial Magnetic Stimulation
Sham Comparator: SHAM stimulation; SHAM iTBS delivered four times daily to an individually defined SHAM region in left dorsolateral prefrontal cortex (DLPFC).	Device: Intermittent Theta Burst Stimulation (iTBS); iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.; Other Names: Repetitive Transcranial Magnetic Stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Resting-state functional connectivity (FC)	Changes in connectivity within and between brain networks	1 hour
Blood oxygenation level dependent (BOLD) activation	Changes in activation resulting from performing a specific functional MRI (fMRI) task	1 hour
Applied Cognition-General Concerns scale	Subjects rate how statements about cognition and attention apply to them, e.g., "Thinking is foggy." Score range is 8-40, with higher scores indicating lesser cognitive concerns.	10 minutes
Profile of Mood States Tension subscale	Subjects are asked to rate how much certain adjectives about their mood apply to them at that moment, e.g., "tense", "nervous", "shaky." Score range: 0-28, higher scores indicating more tension.	5 minutes
Profile of Mood States Vigor subscale	Subjects rate how much mood adjectives apply to them at that moment, e.g., "full of pep," "energetic," "vigorous." Score range 0-28, higher scores indicating more vigor.	5 minutes
Profile of Mood States Dejection subscale	Subjects rate how much mood adjectives apply to them at that moment, e.g., "unworthy." Score range 0-28, higher scores indicating higher dejection.	5 minutes
State Shame and Guilt Scale	Subjects rate how much certain statements apply to them, e.g., "I feel regret." Score range is 10-50, higher scores indicate more shame/guilt.	5-10 minutes
Fawcett-Clark Pleasure Capacity Scale	Subjects anticipate how much they would enjoy a certain scenario, e.g., "you sit watching a beautiful sunset in an isolated part of the world." Score range is 36 to 180, higher scores indicate higher pleasure capacity.	5-10 minutes
Digit-Span Test	Subjects repeat number lists in forward or reverse order (maximum score is 8 forwards and 8 backwards, higher scores indicate better performance).	5 minutes
Tower of London Task	Subjects plan a series of moves to match a start set to a goal set.	5-10 minutes
Delayed Match to Sample Task	Subjects match patterns to a recently viewed sample pattern. Score ranges from 0-30, with higher scores indicating better performance.	5 minutes
The Simon Test	Subjects press different buttons based on incongruent spatial and/or color cues. Scores range from 0-30, with higher scores indicating better performance.	5 minutes
Face-name Associative Paradigm	Subjects must remember names paired with certain faces (DN-A). Scores range from 0-32, with higher scores indicating better performance.	30 minutes
Reading the Mind Through the Eyes Test	Subjects judge another person's mental state by looking at pictures of only their eyes. Score ranges from 0-41, higher scores indicate better performance.	10 minutes

Collaborators and Investigators

• Sponsor: Massachusetts General Hospital
• Collaborators: National Institute of Mental Health (NIMH)

Publications and helpful links

General Publications

• Eldaief MC, Halko MA, Buckner RL, Pascual-Leone A. Transcranial magnetic stimulation modulates the brain's intrinsic activity in a frequency-dependent manner. Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21229-34. doi: 10.1073/pnas.1113103109. Epub 2011 Dec 12.
• Fox MD, Halko MA, Eldaief MC, Pascual-Leone A. Measuring and manipulating brain connectivity with resting state functional connectivity magnetic resonance imaging (fcMRI) and transcranial magnetic stimulation (TMS). Neuroimage. 2012 Oct 1;62(4):2232-43. doi: 10.1016/j.neuroimage.2012.03.035. Epub 2012 Mar 19.

Study record dates

Study Major Dates

• Study Start (Actual): March 12, 2024
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: August 14, 2022
• First Submitted That Met QC Criteria: August 30, 2022
• First Posted (Actual): August 31, 2022

Study Record Updates

• Last Update Posted (Estimated): May 15, 2024
• Last Update Submitted That Met QC Criteria: May 14, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Mood Disorders; Depressive Disorder; Depressive Disorder, Major
• Other Study ID Numbers: 2022P002110; 1R01MH129367-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This project will adhere to the NIH Grant Policy on Sharing of Unique Research Resources including the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources. The results of this research will be made available via publication in scientific journals and through scientific meetings where our findings are reported. Publication of data shall occur during the project, if appropriate, or at the end of the project, consistent with normal scientific practices. All publications will be made publicly available consistent with NIH policies. Such research data will be redacted to prevent the disclosure of personal identifiers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No